Skip Navigation



Annals of Oncology Advance Access published online on October 7, 2008
Annals of Oncology, doi:10.1093/annonc/mdn637
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/2/227    most recent
mdn637v1
Right arrow E-letters: Submit a response
Right arrow E-letters: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Scartozzi, M.
Right arrow Articles by Cascinu, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scartozzi, M.
Right arrow Articles by Cascinu, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

M. Scartozzi*, E. Galizia, S. Chiorrini, R. Giampieri, R. Berardi, C. Pierantoni and S. Cascinu

Clinic of Medical Oncology, Polytechnic University of the Marche Region, Riuniti Hospital, Ancona, Italy

* Correspondence to: Dr M. Scartozzi, Clinica di Oncologia Medica, AO Ospedali Riuniti-Università Politecnica delle Marche, Via Conca, 60020, Ancona, Italy. Tel: +39-715963834; Fax: +39-715964192; E-mail: marioscartozzi{at}libero.it

Background: Arterial hypertension occurring during antiangiogenic therapy has been correlated with the biological inhibition of the vascular endothelial growth factor-related pathway and may represent a possible clinical marker for treatment efficacy. The aim of our study was to retrospectively assess if grades 2–3 hypertension were associated with response to bevacizumab, progression-free survival (PFS) and survival in metastatic colorectal cancer patients treated with first-line bevacizumab.

Patients and methods: Patients with histologically proven, metastatic colorectal cancer receiving bevacizumab as first-line therapy in combination with irinotecan and 5-fluorouracil were eligible for our analysis.

Results: Thirty-nine metastatic colorectal cancer patients were eligible. Eight patients (20%) developed grades 2–3 hypertension. A partial remission was observed in six of eight cases with bevacizumab-related hypertension (75%) and in 10 of 31 (32%) patients with no hypertension (P = 0.04). Median PFS was 14.5 months for patients showing bevacizumab-related hypertension, while it was 3.1 months in those without hypertension (P = 0.04). Median overall survival was not reached in patients with hypertension while it was 15.1 months in the remaining cases (P = 0.11).

Conclusions: Our data indicate that bevacizumab-induced hypertension may represent an interesting prognostic factor for clinical outcome in advanced colorectal cancer patients receiving first-line bevacizumab.

arterial hypertension, bevacizumab, colorectal cancer

Received for publication March 27, 2008. Revision received July 16, 2008. Accepted for publication August 22, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
O. Mir, S. Ropert, J. Alexandre, and F. Goldwasser
Hypertension as a surrogate marker for the activity of anti-VEGF agents
Ann. Onc., May 1, 2009; 20(5): 967 - 970.
[Full Text] [PDF]

Home page
 Ann OncolHome page
B. I. Levy
Blood pressure as a potential biomarker of the efficacy angiogenesis inhibitor
Ann. Onc., February 1, 2009; 20(2): 200 - 203.
[Full Text] [PDF]

E-letters:

Read all E-letters

Hypertension-A prognostic factor for patients receiving Bevacizumab ?
Mark J. Rother
Annals of Oncology, 11 Feb 2009 [Full text]

Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.